Stock A326030 SK BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News SK Biopharmaceuticals Co., Ltd.

Equities

A326030

KR7326030004

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
85,000 KRW +1.19% Intraday chart for SK Biopharmaceuticals Co., Ltd. +5.33% -15.34%
Jan. 30 SK Biopharmaceuticals Swings to Profit in Q4 MT
2023 SK Group Advances Net Zero Transition via Key Renewable Energy Deal MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SK Life Science - XCOPRI CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube
AQ
SK Life Science Celebrates Purple Day Highlighting Partnerships and Tools Designed to Empower People Living with Epilepsy in Their Journey to Achieve Zero Seizures
AQ
SK Biopharmaceuticals Swings to Profit in Q4
MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal
MT
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CI
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference
CI
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd..
CI
Hikma and SK Biopharmaceuticals enter a strategic partnership for the Middle East and North Africa
AQ
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2%
MT
SK Biopharmaceuticals Enters Licensing Agreement with Hikma's Middle East Division
MT
SK Biopharmaceuticals Continues to Report Losses in Q2
MT
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation
CI
SK Biopharmaceuticals Forecasts $1 Billion in US Sales by 2029
MT
SK Biopharmaceuticals Co., Ltd. agreed to acquire 60% interest in ProteoVant Sciences, Inc. from Roivant Sciences Ltd. for $47.5 million.
CI
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
SK Biopharmaceuticals Narrows Loss in Q1
MT
SK Biopharmaceuticals Swings to Loss in Q4
MT
SK to Showcase 40 Carbon Reduction Technologies at CES 2023
AQ
SK Biopharmaceuticals' Anti-Epilepsy Treatment Cenobamate Approve for Sale in France
MT
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A326030 Stock
  4. News SK Biopharmaceuticals Co., Ltd.